Inaqovi (Decitabine, Cedazuridine)

Decitabine is incorporated into cellular DNA where it binds and inactivates DNA methyltransferase enzymes. This inhibition leads to hypomethylation of DNA, re‑activating tumor‑suppressor genes and altering malignant cell growth. Cedazuridine protects decitabine from rapid degradation, allowing sufficient oral exposure.

The prescribed dose of Inaqovi is determined by the treating physician based on the patient’s disease characteristics, laboratory values, and overall health. The product is supplied as a tablet containing 35 mg decitabine and 100 mg cedazuridine, and dosing schedules are individualized by the prescriber.

The safety of Inaqovi in pregnancy and lactation has not been established. Because the drug may affect fetal development, it should be avoided unless the potential benefit justifies the risk. Women of child‑bearing potential should use effective contraception, and breastfeeding is not recommended while on therapy.

To order Inaqovi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any required import documentation.

Inaqovi combines decitabine with cedazuridine to enable oral delivery, whereas traditional hypomethylating agents such as decitabine alone require intravenous infusion. The oral formulation offers greater convenience and may improve patient adherence, while providing comparable efficacy in approved indications.

Inaqovi tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture. Do not expose the product to excessive heat or humidity, and keep it out of reach of children.

Inaqovi is taken orally as a whole tablet with water, typically on a scheduled day each treatment cycle as directed by the prescriber. It should be swallowed whole and not split, chewed, or crushed unless specifically instructed by a healthcare professional.

The most serious risks include severe myelosuppression leading to infections, bleeding, or anemia, as well as potential liver toxicity and pulmonary complications such as interstitial pneumonitis. Patients should be monitored closely for signs of infection, abnormal liver tests, and respiratory symptoms.

Inaqovi is contraindicated in patients with known hypersensitivity to decitabine, cedazuridine, or any excipients in the tablet. It should also be avoided in individuals with active uncontrolled infections or those receiving live vaccines, due to the heightened risk of severe immunosuppression.